Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vertex Pharmaceuticals Incorporated
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Hepatitis C virus Genotype 1 with detectable plasma hepatitis C virus RNA
Have been infected with hepatitis C virus for greater than (\>) 6 months
Seronegative for hepatitis B surface antigen and Human Immunodeficiency Virus 1 and 2
Must agree to use 2 methods of contraception, including 1 barrier method, during and for 24 weeks after the completion of the study (unless the subject is a female of documented non-child-bearing potential)
Female subjects must have a negative pregnancy test at all visits before the first dose
You may not be if
Received any approved or investigational drug or drug regimen for the treatment of hepatitis C
Any medical contraindications to Pegylated Interferon Alfa 2a or Ribavirin therapy
Any other cause of significant liver disease in addition to hepatitis C; this may include but is not limited to, hepatitis B, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, Nonalcoholic Steatohepatitis or primary biliary cirrhosis
Diagnosed or suspected hepatocellular carcinoma
Histologic evidence of hepatic cirrhosis (including compensated cirrhosis) based on a liver biopsy taken within 2 years before study start
Alcohol abuse or excessive use in the last 12 months
Participation in any investigational drug study within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study)
